Education
About Us
Working with TipRanks
Follow Us
Shilpa Medicare Limited (IN:SHILPAMED)
:SHILPAMED
SHILPAMED Stock Chart & Stats
₹319.90
-₹8.10(-0.96%)
At close: 4:00 PM EST
₹319.90
-₹8.10(-0.96%)
Day’s Range― - ―
52-Week Range₹260.00 - ₹501.60
Previous CloseN/A
Volume218.26K
Average Volume (3M)38.83K
Market Cap
₹62.57B
Enterprise Value₹71.60B
Total Cash (Recent Filing)₹285.24M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)41.7
Beta0.98
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)2.28
Shares Outstanding195,581,820
10 Day Avg. Volume85,780
30 Day Avg. Volume38,829
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)2.70
Price to Sales (P/S)4.98
P/FCF Ratio-57.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.9
Revenue Forecast (FY)₹14.68B
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 68.12% gross margin indicates durable production and pricing advantages in complex oncology APIs and formulations. High gross margins provide structural cushion to fund R&D and absorb pricing pressure, supporting long-term profitability even if operating costs fluctuate.
Diversified Specialty Business ModelA multi-pronged model (APIs, finished dosages, CDMO and biologics) anchors revenue across product life cycles and customers. This reduces single-product risk, leverages complex manufacturing know-how, and supports recurring contract revenue and higher-margin specialty work over the medium term.
Improving Leverage And Strong Equity BaseMaterial reduction in leverage and a 71.65% equity ratio enhance financial resilience, lowering refinancing risk and enabling capital allocation for capacity, compliance, or strategic deals. A stronger balance sheet underpins long-term investments in complex manufacturing.
Bears Say
Negative Free Cash FlowSignificant capex drove free cash flow negative despite stable operating cash flow. Persistent negative FCF can force external financing or slow discretionary R&D and commercialization investments, constraining sustainable growth and shareholder return over coming quarters.
Operating Efficiency DeteriorationA sharp drop in EBIT margin signals higher operating costs or lower operating leverage. If structural, this compresses the conversion of strong gross profit into sustainable earnings, reducing funds available for growth and weakening resilience to pricing or reimbursement shifts.
Modest Returns On EquityROE of ~3.3% remains low relative to capital intensity, indicating limited profit generation from equity. Low returns can make it harder to justify heavy capital investments in specialized capacity and may pressure long-term shareholder value unless operational efficiency or pricing improves.
Shilpa Medicare Limited News
SHILPAMED FAQ
What was Shilpa Medicare Limited’s price range in the past 12 months?
Shilpa Medicare Limited lowest stock price was ₹260.00 and its highest was ₹501.60 in the past 12 months.
What is Shilpa Medicare Limited’s market cap?
Shilpa Medicare Limited’s market cap is ₹62.57B.
When is Shilpa Medicare Limited’s upcoming earnings report date?
Shilpa Medicare Limited’s upcoming earnings report date is May 21, 2026 which is in 81 days.
How were Shilpa Medicare Limited’s earnings last quarter?
Shilpa Medicare Limited released its earnings results on Feb 06, 2026. The company reported ₹2.28 earnings per share for the quarter, missing the consensus estimate of ₹2.8 by -₹0.52.
Is Shilpa Medicare Limited overvalued?
According to Wall Street analysts Shilpa Medicare Limited’s price is currently Overvalued.
Does Shilpa Medicare Limited pay dividends?
Shilpa Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.16%. See more information on Shilpa Medicare Limited dividends here
What is Shilpa Medicare Limited’s EPS estimate?
Shilpa Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shilpa Medicare Limited have?
Shilpa Medicare Limited has 195,581,820 shares outstanding.
What happened to Shilpa Medicare Limited’s price movement after its last earnings report?
Shilpa Medicare Limited reported an EPS of ₹2.28 in its last earnings report, missing expectations of ₹2.8. Following the earnings report the stock price went down -0.663%.
Which hedge fund is a major shareholder of Shilpa Medicare Limited?
Currently, no hedge funds are holding shares in IN:SHILPAMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shilpa Medicare Limited
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (API's), intermediates, and formulations in India, the United States, Europe, and internationally. It offers oncology and non-oncology API's.; and new drug delivery systems, peptides/biotech products, specialty chemicals, etc. The company also provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. It is also involved in the wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is headquartered in Raichur, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Dr. Reddy's Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―
Sanofi India Limited
―